| [1] | TRESUKOSOL D,SUKTITIPAT B,HUNNANGKUL S,et al.Effects of cytochrome P4502C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease[J].PLoS One,2014,9(10):87. |
| [2] | JANG JS,CHO KI,JIN HY,et al.Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel[J].Am J Cardiol,2012,110(4):502. |
| [3] | CHEN DY,WANG CY,WEN MS,et al.Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population [J].PLoS One,2012,7(6):102. |
| [4] | BARKER CM,MURRAY SS,TEIRSTEIN PS,et al.Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity[J].JACC Cardiovasc Interv,2010,3(10):1008. |
| [5] | MEHTA SR,YUSUF S,PETERS RJ,et al.Effects of pretreatment with elopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study[J].Lancet,2001,358(9281):527. |
| [6] | MEHTA SR,TANGUAY JF,EIKELBOOM JW,et al.Double-dose versus standard-dose elopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes:a randomised factorial trial[J].Lancet,2010,376(9748):1233. |
| [7] | TERPENING C.Clopidogrel:a pharmacogenormic perspective on its use in coronary artery disease[J].Clin Med Insights Cardiol,2010,4:117. |
| [8] | PRICE MJ,MURRAY SS,ANGIOLILLO DJ,et al.Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention:the GIFT (GenotypeInformation and Functional Testing) study[J].Am Coll Cardiol,2012,59(22):1928. |
| [9] | WU H,QIAN J,SUN A,et al.Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment [J].Circ,2012, 76(12):2773. |
| [10] | ZHANG L,CHEN Y,JIN Y,et al.Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients[J].Thromb Res,2013,132(1):81. |
| [11] | TAUBERT D,BOUMAN HJ,VAN WERKUM JW,et al.Cytochrome P-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360(4):354. |
| [12] | COLLET JP,HULOT JS,ANZAHA G,et al.High doses of clopidogrel to overcome genetic resistance:the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)[J].JACC Cardiovas Interv,2011,4(4):392. |
| [13] | MEGA JL,HOCHHOLZER W,FRELINGER AL,et al.Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J].JAMA,2011,306(20):2221. |
| [14] | CUISSET T,QUILICI J,COHEN W,et al.Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome[J].Am J Cardiol,2011,108(6):760. |
| [15] | JEONG YH,KIM IS,PARK Y,et al.Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day:results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study[J].JACC Cardiovasc Interv,2010,3(7):731. |
| [16] | PARK J.Backtracking on CYP2C19 genotyping in clopidogrel therapy?[J].Biomark Med,2010,363(18):1704. |